EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
STATUS AND THE IMPACT ON CLINICAL OUTCOMES
IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Huang HM1, Wei Y1, Wang JJ1, Ran FY1, Wen Y2, Chen QH3, Zhang BF1,*
*Corresponding Author: Dr. Bingfei Zhang, Sinopharm Dongfeng General Hospital, Hubei University
of Medicine, No. 16 Daling Road, 442008, Shiyan, Hubei, China. Tel.: + 86-29-8272597,
Email: dfzyysszx@163.com
page: 29
|
|
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics,
2020. CA Cancer J Clin. 2020; 70(1): 7-30.
2. Duma N, Santana-Davila R, Molina JR. Non-Small
Cell Lung Cancer: Epidemiology, Screening, Diagnosis,
and Treatment. Mayo Clin Proc. 2019; 94(8):
1623-1640.
3. Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL,
Santomé L, Barón F, et al. EGFR testing and clinical
management of advanced NSCLC: a Galician Lung
Cancer Group study (GGCP 048- 10). Cancer Manag
Res. 2016; 8(11-20.
4. Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni
V, Tagliamento M, et al. Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. Int J Mol
Sci. 2021; 22(5):.
5. Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN,
et al. Comparison of the efficacy and safety of EFGR
tyrosine kinase inhibitor monotherapy with standard
second-line chemotherapy in previously treated
advanced non-small-cell lung cancer: a systematic
review and meta-analysis. Asian Pac J Cancer Prev.
2012; 13(10): 5177-5182.
6. Lindeman NI, Cagle PT, Beasley MB, Chitale DA,
Dacic S, Giaccone G, et al. Molecular testing guideline
for selection of lung cancer patients for EGFR
and ALK tyrosine kinase inhibitors: guideline from
the College of American Pathologists, International
Association for the Study of Lung Cancer, and Association
for Molecular Pathology. J Thorac Oncol.
2013; 8(7): 823-859.
7. Hanna N, Johnson D, Temin S, Baker S, Brahmer J,
Ellis PM, et al. Systemic Therapy for Stage IV Non-
Small-Cell Lung Cancer: American Society of Clinical
Oncology Clinical Practice Guideline Update. J
Clin Oncol. 2017; 35(30): 3484-3515.
8. Midha A, Dearden S, McCormack R. EGFR mutation
incidence in non-small-cell lung cancer of adenocarcinoma
histology: a systematic revie w and
global map by ethnicity (mutMapII). Am J Cancer
Res. 2015; 5(9): 2892-2911.
9. Lee DH, Srimuninnimit V, Cheng R, Wang X, Orlando
M. Epidermal Growth Factor Receptor Mutation
Status in the Treatment of Non-small Cell Lung
Cancer: Less ons Learned. Cancer Res Treat. 2015;
47(4): 549-554.
10. Choi YL, Sun JM, Cho J, Rampal S, Han J, Parasuraman
B, et al. EGFR mutation testing in patients with
advanced non-small cell lung cancer: a comprehensive
evaluation of real-world practice in an East Asian
tertiary hospital. Plos One. 2013; 8(2): e56011.
11. Szumera-Cie Kiewicz A, Olszewski WT, Tysarowski
A, Kowalski DM, G Ogowski M, Krzakowski M, et
al. EGFR mutation testing on cytological and histological
samples in non-small cell lung cancer: a
Polish , single institution study and systematic review
of European incidence. Int J Clin Exp Pathol. 2013;
6(12): 2800-2812.
12. Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis
P, Charpidou A, Christodoulou C. Epidemiological
Characteristics, EGFR Status and Management
Patterns of Advanced Non-small Cell Lung Cancer
Patients: The Greek REASON Observational Registry
Study. Anticancer Res. 2018; 38(6): 3735-3744.
13. Haghgoo SM, Khosravi A, Mortaz E, Pourabdollah-
Toutkaboni M, Seifi S, Sabour S, et al. Prognostic
value of rare and complex mutations in EGFR and
serum levels of soluble EGFR and its ligan ds in nonsmall
cell lung carcinoma patients. Clin Biochem.
2017; 50(6): 293-300.
14. Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy
M, El Karak F, et al. EGFR mutation status in Middle
Eastern patients with non-squamous non-small
cell lung carcinoma: A si ngle institution experience.
Cancer Epidemiol. 2015; 39(6): 1099-1102.
15. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi
M, Fujimoto M, Kawakami F, et al. Validation of the
IASLC/ATS/ERS lung adenocarcinoma classification
for prognosis and association with EGFR and KRAS
gene mutations: analysis of 440 Japanese patients. J
Thorac Oncol. 2013; 8(1): 52-61.
16. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM,
Khoa MT, et al. A prospective, molecular epidemiology
study of EGFR mutations in Asian patients with
advanced non-small-cell lung cancer of adenocarcinoma
histology (PIONEER). J Thorac Oncol. 2014;
9(2): 154-162.
17. Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK,
Du X, et al. EGFR mutation testing practices within
the Asia Pacific region: results of a multicenter diagnostic
survey. J Thorac Oncol. 2015; 10(3): 438-445.
18. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et
al. High incidence of EGFR mutations in Korean
men smokers with no intratumoral heterogeneity of
lung adenocarcinomas: correlation with histologic
subtypes, EGFR/TTF-1 expressions, and clinical
features. J Thorac Oncol. 2012; 7(2): 323-330.
19. Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY,
et al. A comprehensive review of uncommon EGFR
mutations in patients with non-small cell lung cancer.
Lung Cancer. 2017; 114(96-102.
20. Jackman DM, Miller VA, Cioffredi LA, Yeap BY, J Nne
PA, Riely GJ, et al. Impact of epidermal growth factor
receptor and KRAS mutations on clinical outcomes
in previously untr eated non-small cell lung cancer
patients: results of an online tumor registry of clinical
trials. Clin Cancer Res. 2009; 15(16): 5267-5273.
21. Rosell R, Moran T, Queralt C, Porta R, Cardenal F,
Camps C, et al. Screening for epidermal growth factor
receptor mutations in lung cancer. N Engl J Med.
2009; 361(10): 958-967.
22. Massarelli E, Johnson FM, Erickson HS, Wistuba
II, Papadimitrakopoulou V. Uncommon epidermal
growth factor receptor mutations in non-small cell lung cancer and their mechanism s of EGFR tyrosine
kinase inhibitors sensitivity and resistance. Lung
Cancer. 2013; 80(3): 235-241.
23. Esteban E, Majem M, Martinez Aguillo M, Martinez
Banaclocha N, Dómine M, Gómez Aldaravi
L, et al. Prevalence of EGFR mutations in newly
diagnosed locally advanced or metastatic non-small
cell lung cancer Spanish patients and its association
with histological subtypes and clinical features: The
Spanish REASON study. Cancer Epidemiol. 2015;
39(3): 291-297.
24. Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus
I, Lacave R, Lacroix L, et al. Rare EGFR exon 18 and
exon 20 mutations in non-small-cell lung cancer on
10 117 patients: a multicent re observational study
by the French ERMETIC-IFCT network. Ann Oncol.
2014; 25(1): 126-131.
25. Lee B, Lee T, Lee SH, Choi YL, Han J. Clinicopathologic
characteristics of EGFR, KRAS, and ALK
alterations in 6,595 lung cancers. Oncotarget. 2016;
7(17): 23874-23884.
26. Calibasi-Kocal G, Amirfallah A, Sever T, Umit Unal
O, Gurel D, Oztop I, et al. EGFR mutation status in a
series of Turkish non-small cell lung cancer patients.
Biomed Rep. 2020; 13(2): 2.
27. Gahr S, Stoehr R, Geissinger E, Ficker JH, Brueckl
WM, Gschwendtner A, et al. EGFR mutational status
in a large series of Caucasian European NSCLC
patients: data from daily practice. Br J Cancer. 2013;
109(7): 1821-1828.
28. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley
MB, Bernicker EH, et al. Updated Molecular
Testing Guideline for the Selection of Lung Cancer
Patients for Treatment With Targeted Tyrosine Kinase
Inhibitors: Guideline From the College of American
Pathologists, the International Association for
the Study of Lung Cancer, and the Association for
Molecular Pathology. J Thorac Oncol. 2018; 13(3):
323-358.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
